| Vol. 12.00 – 8 January, 2021 |
| |
|
|
| Researchers showed that activated endothelial cells were enriched in castration-resistant prostate cancer and promoted cancer cell invasion. They created a user-friendly web interface for users to explore the sequenced data. [Nature Cell Biology] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists showed that microRNA-194 (miR-194) is a regulator of epithelial-neuroendocrine (NE) transdifferentiation. In clinical prostate cancer (PC) samples, miR-194 expression and activity were elevated in NEPC and inversely correlated with androgen receptor signaling. [Cell Reports] |
|
|
|
| Investigators report that monoamine oxidase A (MAOA) is a clinically and functionally important mediator of perineural invasion (PNI) in prostate cancer (PC). MAOA promoted PNI of PC cells in vitro and tumor innervation in an orthotopic xenograft model. [Oncogene] |
|
|
|
| Scientists report that the Wnt secretion mediator Wntless (WLS) is a major driver of neuroendocrine prostate cancer and aggressive tumor growth in vitro and in vivo. [iScience] |
|
|
|
| To determine vitamin D regulation of prostatic epithelial differentiation, patient-derived benign prostate epithelial organoids were grown in vitamin D deficient or sufficient conditions. [iScience] |
|
|
|
| The authors showed that an androgen-deprivation therapy-stimulated transcription factor, ZBTB46, upregulated NGF via ZBTB46 mediated-transcriptional activation of nerve growth factor. [Communications Biology] |
|
|
|
| Investigators performed a direct, unbiased chemical genetic screen to identify pro-viral integration site for Moloney murine leukemia virus-1 (PIM1) substrates in prostate cancer cells. [Communications Biology] |
|
|
|
|
| The authors review the molecular mechanisms that enable cancer cells to switch from an androgen receptor (AR)-positive to an AR-negative disease and efforts to prevent/revert this process and thereby maintain/restore AR-dependence. [Oncogene] |
|
|
|
| Scientists outline the role of LOX-1 in tumor spreading and metastasis, evidencing its function in VEGF induction, HIF-1alpha activation, and MMP-9/MMP-2 expression, pushing up the neoangiogenic and the epithelial-mesenchymal transition process in glioblastoma, osteosarcoma, prostate, colon, breast, lung, and pancreatic tumors. [Cancer Gene Therapy] |
|
|
|
|
| Myovant Sciences and Pfizer Inc. announced a collaboration to develop and commercialize relugolix – a once-daily, oral gonadotropin-releasing hormone receptor antagonist – in oncology and women’s health in the US and Canada. Pfizer will also receive an exclusive option to commercialize relugolix in oncology outside the US and Canada, excluding certain Asian countries. [Myovant Sciences GmbH.] |
|
|
|
|
| January 13 – 14, 2021 Virtual |
|
|
|
|
|
| Medical University of GdaÅ„sk – GdaÅ„sk, Poland |
|
|
|
| STEMCELL Technologies, Inc. – Burnaby, British Columbia, Canada |
|
|
|
| Fondazione Human Technopole – Milan, Italy |
|
|
|
| Scripps Research Institute – La Jolla, California, United States |
|
|
|
| Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
|